Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.
OBJECTIVE
To investigate whether CD30 expression is correlated with anaplastic morphology, and whether this correlated with a better survival in large cell B cell lymphomas, as has been described for T cell lymphomas.


METHODS
CD30 expression was investigated using frozen sections in a series of 146 large cell B cell lymphomas. Clinical data and follow up information were collected from 25 lymphomas with strong CD30 expression, 30 lymphomas with partial CD30 expression, and a control group of 25 lymphomas which did not express CD30.


RESULTS
Morphological distinction between anaplastic and non-anaplastic tumours was difficult. Of the cases with an anaplastic morphology, 50% were CD30 positive, as were 24% of the polymorphic centroblastic B cell lymphomas. Only 65% of the morphologically non-anaplastic tumours were completely CD30 negative. There was no difference in survival among patients with lymphomas expressing CD30 and those that did not. Patients with morphologically anaplastic B cell lymphomas did not differ in their survivals from those with other high grade B cell lymphomas. Clinical stage at presentation was the only variable that was significantly associated with survival.


CONCLUSIONS
CD30 expression occurs frequently in large cell B cell lymphomas and is poorly related to anaplastic morphology. Morphological distinction between anaplastic and non-anaplastic tumours is difficult. In contrast to T cell lymphomas, CD30 positive B cell lymphomas do not show a relatively favourable clinical course. The results presented here raise serious doubts as to whether large cell B cell lymphoma, based on the expression of CD30 or anaplastic morphology, can really be termed a separate entity.
Noorduyn
L A
LA
Department of Pathology, Academic Medical Centre, Amsterdam, The Netherlands.
de Bruin
P C
PC
van Heerde
P
P
van de Sandt
M M
MM
Ossenkoppele
G J
GJ
Meijer
C J
CJ
D005500:Follow-Up Studies; D006801:Humans; D017730:Ki-1 Antigen / Q000032:analysis*; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D009367:Neoplasm Staging
D017730:Ki-1 Antigen